Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.46 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 9/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30013082 | 0.85 | ALDH1A1 (0.46) | ALDH1A1MAPTLMNAHPGDNPSR1 | |
| SCHEMBL17059541 | 0.84 | ALDH1A1 (0.44) | ALDH1A1MAPTLMNAHPGDNPSR1 | |
| SCHEMBL23728631 | 0.83 | CASP3 (0.44) | ALDH1A1MAPTLMNAHPGDNPSR1 | |
| SCHEMBL17479970 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNAHPGDNPSR1 | |
| SCHEMBL17480066 | 0.83 | ALDH1A1 (0.41) | ALDH1A1MAPTLMNAHPGDNPSR1 | |
| SCHEMBL872752 | 0.83 | CASP3 (0.44) | ALDH1A1MAPTLMNAHPGDNPSR1 | |
| SCHEMBL9886578 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNAHPGDNPSR1 | |
| SCHEMBL15281424 | 0.83 | CASP3 (0.44) | ALDH1A1MAPTLMNAHPGDNPSR1 | |
| SCHEMBL30410248 | 0.82 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAHPGDNPSR1 | |
| SCHEMBL25695323 | 0.82 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9320741-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9301962-B2 | Male contraceptive compositions and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| WO-2011143651-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | SHBG, CYP19A1, CYP17A1 | ALDH1A1 1692/4885MAPT 4052/4885LMNA 288/4885 |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | BRPF3, EP300, BRD3 | ALDH1A1 3670/4885MAPT 2072/4885LMNA 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.